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Objective: To facilitate development of novel disease-modifying therapies for lysosomal storage disorder (LSDs)
characterized by nervous system involvement such as metachromatic leukodystrophy (MLD), molecular markers for
monitoring disease progression and therapeutic response are needed. To this end, we sought to identify blood tran-
scripts associated with the progression of MLD.
Methods: Genome-wide expression analysis was performed in primary T lymphocytes of 24 patients with MLD com-
pared to 24 age- and sex-matched healthy controls. Genes associated with MLD were identified, confirmed on a
quantitative polymerase chain reaction platform, and replicated in an independent patient cohort. mRNA and protein
expression of the prioritized gene family of metallothioneins was evaluated in postmortem patient brains and in
mouse models representing 6 other LSDs. Metallothionein expression during disease progression and in response to
specific treatment was evaluated in 1 of the tested LSD mouse models. Finally, a set of in vitro studies was planned
to dissect the biological functions exerted by this class of molecules.
Results: Metallothionein genes were significantly overexpressed in T lymphocytes and brain of patients with MLD and
generally marked nervous tissue damage in the LSDs here evaluated. Overexpression of metallothioneins correlated
with measures of disease progression in mice and patients, whereas their levels decreased in mice upon therapeutic
treatment. In vitro studies indicated that metallothionein expression is regulated in response to oxidative stress and
inflammation, which are biochemical hallmarks of lysosomal storage diseases.
Interpretation: Metallothioneins are potential markers of neurologic disease processes and treatment response in LSDs.
ANN NEUROL 2014;75:127–137
L
ysosomal storage disorders (LSDs) comprise a class of
inherited diseases characterized by disruption of normal
lysosomal function. Incompletely degraded substrates accu-
mulate, accompanied by cellular dysfunction and death.
Neuroinflammation occurs as a reaction to substrate accu-
mulation within microglia and astrocytes or as a response
to primary neuronal or oligodendroglial damage.
1 Neuro-
inflammation is of particular relevance in mediating the
neuropathology associated with LSDs. Metachromatic leu-
kodystrophy (MLD; Online Mendelian Inheritance in
Man database #250100), a demyelinating LSD caused by
mutations in the arylsulfatase A (ARSA) gene,
2 is a proto-
typical example of LSD with progressive accumulation of
undegraded sulfatides in the nervous system as well as
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autosomal recessive disease with an estimated incidence of
1:40,000 to 1:100,000.
3 The disease is classified into late
infantile, juvenile, and adult forms according to the age at
onset of symptoms. Clinical manifestations, which consist
of unrelenting motor and cognitive impairment, progress
rapidly and are more severe in the early onset variants, fre-
quently leading to death within the first decade of life. A
correlation between MLD phenotype and ARSA mutations
has recently been suggested.
4,5
Considerable research activity is currently focused on
developing strategies to target brain disease in MLD and
other LSDs with central nervous system (CNS) involve-
ment. Gene therapy,
6–8 enzyme replacement therapy,
9 and
small molecular weight compounds are advancing from
preclinical to early clinical studies and may enable disease-
modifying treatments for these thus far incurable, devastat-
ing diseases. Clinical phenotypes and disease progression
are highly variable, thus complicating the study of new
therapies. Tracking aspects of the complex CNS pathology
and their response to novel treatments is particularly chal-
lenging. To facilitate therapeutics development, biomarkers
of brain disease that can be monitored in support of clini-
cal endpoints would be helpful.
Molecular changes have been increasingly appreci-
ated in various neurological diseases in cells outside the
nervous system, including in circulating blood cells.
10–13
We hypothesized that deciphering the molecular networks
progressively perturbed in patients with MLD, and possi-
bly in other LSDs, could highlight novel markers poten-
tially useful for accelerating therapeutics development.
Materials and Methods
Human Studies
Peripheral blood mononuclear cells (PBMCs) were obtained by
drawing blood from MLD patients and age- and sex-matched
healthy controls at San Raffaele Scientific Institute upon
informed consent collection. A T-lymphocyte culture was estab-
lished by stimulating PBMCs with 1lg/ml phytohemagglutinin
and 300U/ml interleukin-2 in Iscove modified Dulbecco
medium 5% human serum for 10 days.
Postmortem snap-frozen or formalin-fixed human brain
samples and the cerebrospinal fluid (CSF) from patients and
controls were obtained from the National Institute of Child
Health and Human Development Brain and Tissue Bank for
Developmental Disorders at University of Maryland, Baltimore.
Mouse Studies
All the animal procedures described herein (on mouse models
of different LSDs at a late symptomatic stage and on age-
matched wild-type [WT] C57 siblings) were approved by the
institutional animal care and use committee of the San Raffaele
Scientific Institute.
Primary cultures of cortical astrocytes and primary cocul-
tures of astrocytes and microglia were stimulated 10 to 14 days
after plating as follows: 6 hours of incubation with 10ng/ml lipo-
polysaccharide (LPS), 100lMH 2O221mM L-buthionine-sulfoxi-
mine (BSO) or 1mM Trolox; or 24 hours of incubation with
10lM dexamethasone or 10% serum from WT and globoid cell
leukodystrophy (GLD) mice.
Microarray Analysis
Biotinilated cRNA (Ambion, Austin, TX) from MLD patients
and controls was hybridized on 6-sample Illumina (San Diego,
CA) WG_v3 Beadchips. Microarray analysis was performed
according to the Minimum Information about a Microarray
Experiment guidelines. Microarray data have been deposited in
National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus with accession number GSE23350 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc5GSE23350).
Single gene analysis, significance analysis of microarrays (SAM),
and ingenuity pathway analysis were performed on normalized data
only on probes with a detection p<0.0001 on at least 1 array.
Metallothionein Detection
Quantitative polymerase chain reaction (qPCR) was performed
using Taqman Gene Expression Assay primers and probes for
human MT1A, MT1E, MT2A, MTE, mouse Mt1, Mt2, Lrp2
and Cxcl11, and human and mouse GAPDH as reference genes
(Life Technologies, Carlsbad, CA).
Mouse a-metallothionein (a-MT) antibody (DAKO, Carpin-
teria, CA; clone E9) was used for MT detection in immunohisto-
chemical stainings on formalin-fixed human brains (1:50) together
with routine hematoxylin & eosin and Kluver–Barrera methods,
and in Western blot analyses (1:1,000) on brain samples and CSF.
Please also refer to the Supplementary Methods.
Results
MTs Are Overexpressed in the T Lymphocytes
of MLD Patients
To identify biomarkers for MLD, we performed a genome-
wide expression analysis on primary T lymphocytes from 24
MLD patients and 24 age- and sex-matched healthy con-
trols. T cells were chosen because a well-established culture
method
14–16 allows obtaining a valuable quantity of good-
quality RNA even starting from the limited amount of
blood that could be drawn from pediatric patients. More-
over, arylsulfatase A is known to be biologically active in
this subset of circulating cells.
17 We found 23 transcripts
(targeted by 26 probes) that were significantly differentially
expressed in patients compared to controls, with a false dis-
covery rate of <0.01 by SAM with a cutoff fold change of
1.5. Twenty transcripts were overexpressed and 3 were
underexpressed in patients (Fig 1A and Table). Four
members of the metallothionein (MT) gene family (MT1A,
MT1E, MT2A,a n dMTE-MT1IP;N C B IR e f S e q :
NM_005946.2, NM_175617.3, NM_005953.3, and
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MT1P3-C20ORF127 were overexpressed in primary T lym-
p h o c y t e so fp a t i e n t sw i t hM L D .O v e r e x p r e s s i o no fM T si n
patients was confirmed by qPCR (see Fig 1B). To confirm
these associations in an independent population, we eval-
uated MT expression in cultured primary T lymphocytes
derived from a new cohort of 7 early onset MLD patients
and 9 controls. Satisfyingly, marked MT overexpression was
confirmed in this independent population (see Fig 1C).
To gain clues on the pathways altered in MLD and
the possible correlation between their perturbation and
MTs, we analyzed the expression levels and ontology of the
11,883 genes from our microarray study through Ingenuity
Pathway Analysis (Ingenuity Systems, Redwood City, CA)
software. Interestingly, the majority of the top 10 most sig-
nificantly perturbed pathways (p<0.05, Fisher exact test)
in patients were related to cellular oxidative stress and/or
inflammatory responses. Most of the molecules belonging
to these pathways were significantly upregulated in MLD
patients as compared to controls (Supplementary Fig S1).
MTs Are Overexpressed in the Brain of MLD
Patients
To investigate whether MTs are overexpressed in patients’
brains in addition to patient-derived T lymphocytes, we ana-
lyzed postmortem brain tissue of 4 MLD patients who died
at advanced disease stages, compared to 4 age-, sex-, post-
mortem interval–, and RNA quality–matched controls with-
out neurologic disease. MTs were robustly overexpressed in
the frontal cortex of patients with MLD as compared to
controls by qPCR (Fig 2A). MT overexpression was particu-
larly striking in the white matter, consistent with the preva-
lent involvement of myelin-ric hr e g i o n si nt h i sd i s e a s e .O f
note, MT overexpression in the brain of MLD patients
greatly exceeded the levels observed in primary T lympho-
cytes (average MT fold change of 25.5 in brain tissue, com-
pared to average fold change of 1.6 in T lymphocytes).
Immunoreactivity against MTs was elevated in both
the white and gray matter of postmortem brains from
the same MLD patients, particularly in astrocytes (see
Fig 2B). Consistent with the disease, a diffuse disruption
of tissue architecture was also observed, particularly in
the white matter, with presence of engulfed tissue macro-
phages and disruption of the myelin reticulum.
MTs Are General Markers of Nervous Tissue
Damage in LSDs
More than 40 different LSDs exist, the majority of which
involve the nervous system.
18 We assessed whether MTs
are overexpressed in other LSDs with nervous system
involvement in addition to MLD. We analyzed MT
expression in postmortem brain samples from a total of
FIGURE 1: Metallothioneins (MTs) are overexpressed in T
lymphocytes of patients with metachromatic leukodystrophy
(MLD). (A) Twenty-six probes, including 5 MTs (marked in
gray), are differentially expressed in T lymphocytes of 24
patients with MLD compared to 24 age- and sex-matched
controls (CTR; fold change>1.5; false discovery rate<0.01).
In this heat map, each column represents an individual and
each row represents a probe. As shown in the color bar,
overexpression is visualized in shades of red and underex-
pression is visualized in shades of blue. (B, C) Overexpres-
sion of MT1A, MT1E, MT2A, and MTE is confirmed by
quantitative polymerase chain reaction on T lymphocytes of
MLD patients from the microarray cohort (MT1A, fold
change51.33; MT1E, fold change52.29, p50.031; MT2A,
fold change51.66, p50.037; MTE, fold change51.25; B)
and from an independent cohort of newly recruited early
onset MLD patients (n57) and age- and sex-matched con-
trols (n59; MT1A, fold change52.25; MT1E, fold change-
59.66, p50.015; MT2A, fold change54.57, p50.0073;
MTE, fold change53.14; C). Means6standard error of the
mean are shown. *p < 0.05; **p < 0.01.
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January 2014 129FIGURE 2: Metallothioneins (MTs) are overexpressed in the brains of metachromatic leukodystrophy (MLD) patients. (A) Rela-
tive mRNA abundance of MT1A, MT1E, MT2A, and MTE in the white and gray matter of the frontal cortex of 4 MLD patients
compared to 4 controls (CTR; mean6standard error of the mean; *p<0.05). (B) Immunohistochemistry images of the hematox-
ylin & eosin (H&E), Kluver–Barrera, and a-MT stainings on white and gray matter of a representative MLD brain and a related
CTR brain (original magnification, 320). Strong immunoreactivity for MTs can be observed in MLD in subcortical white matter
areas and in cortical regions, particularly restricted to cells morphologically identifiable as astrocytes (asterisks). MLD brain
samples show diffuse disruption of the normal cytoarchitecture, with medium-to-large tissue macrophages engulfing the peri-
vascular zones of the white matter (arrows). Kluver–Barrera staining for myelin highlights diffuse dysmyelination in subcortical
areas, with granular overload of phospholipidic components of myelin in the cytoplasm of the tissue macrophages
(arrowheads).20 patients affected by different LSDs with CNS involve-
ment, such as mucopolysaccharidosis type I (MPSI),
mucopolysaccharidosis type-III (MPSIII), Niemann–Pick
disease (NPC), neuronal ceroidolipofuscinosis (NCL),
and Sandhoff disease (SD), comparing them with the
expression values in 17 age-, sex-, postmortem interval–,
and RNA quality–matched controls without neurologic
disease. MTs (MT1A, MT1E, MT2A, and MTE) were
significantly overexpressed in frontal cortex homogenates
from LSD patients versus controls (Fig 3A, B and Sup-
plementary Fig S2). Expression changes for each of 4
MTs in the overall group of LSDs with CNS involve-
ment versus controls are shown in Figure 3A. Expression
changes for MT2A in each of the 6 LSDs with CNS
involvement are shown separately in Figure 3B. Expres-
sion changes for MT1A, MT1E, and MTE in the indi-
vidual LSDs are shown in Supplementary Figure S2.
The increase in MT protein expression was con-
firmed by immunoblot (see Fig 3C). Relevant for future
clinical biomarker assay development, MT protein levels
appeared elevated also in the CSF of an LSD patient for
whom postmortem CSF was available (see Fig 3D).
To further confirm that brain involvement in LSDs
is associated with MT overexpression, we analyzed animal
models of different LSDs. Mice modeling MLD, globoid
cell leukodystrophy (GLD), MPSI, MPSIII, and SD were
analyzed at late symptomatic stages that are characterized
by demyelination and/or neurodegeneration of various
severity. Murine Mt1 and Mt2, orthologs of the human
MT isoforms, were significantly overexpressed in brain in
these model mice (Supplementary Fig S3A). As observed
in humans, the magnitude of overexpression varied across
different LSDs, with the mouse model for GLD showing
the highest transcript levels (fold change: 5.5 for Mt1 and
8.0 for Mt2). Immunohistochemistry confirmed MT over-
expression at the protein level in brain samples from GLD
mice and suggested that MTs are expressed predominantly
by reactive astrocytes (see Supplementary Fig S3B, C).
We then began to estimate the relative specificity of
MT overexpression as a marker for an MLD-relevant
molecular process. We analyzed 5 large, publicly available
blood expression data sets from patients with another neu-
roinflammatory disease (multiple sclerosis), as well as from
2 neurodegenerative diseases with a neuroinflammatory
contribution (Parkinson disease) or without a major neu-
roinflammatory component (Huntington disease). Satisfy-
ingly, in these in silico analyses the MTs MT1A, MT1E,
MT2A,a n dMTE were not overexpressed in blood cells
from a total of 181 disease controls with other inflamma-
tory or degenerative neurologic disease and 101 controls
free of neurologic diseases (Supplementary Fig S4A, B).
Similarly, no significant change in Mt1 and Mt2 expres-
sion levels could be appreciated in the blood or in the
brain of experimental autoimmune encephalomyelitis
(EAE) mice, modeling multiple sclerosis, throughout the
FIGURE 3: Metallothioneins (MTs) are general markers of
nervous tissue damage in lysosomal storage disorders
(LSDs). (A) Cumulative expression data of MT1A, MT1E,
MT2A, and MTE in brain from LSD patients (n520) com-
pared to controls (CTR; n517; mean6standard error of the
mean [SEM]; **p<0.01). (B) Representative relative mRNA
abundance of MT2A for the separately analyzed LSDs (mean
6SEM; **p<0.01 with 1-way analysis of variance and post
hoc Dunnett analysis; metachromatic leukodystrophy [MLD],
n54; mucopolysaccharidosis type I [MPSI], n53; mucopoly-
saccharidosis type-III [MPSIII], n54; Niemann–Pick disease
[NPC], n53; neuronal ceroidolipofuscinosis [NCL], n54;
Sandhoff disease [SD], n52; CTR, n517). (C) Western blot
immunoreactivity for MT proteins on samples from 5 LSD
brains and 3 related CTR subjects. a-actin immunoreactivity
was assessed to control for protein loading; purified MT1
protein was used as positive control (CO1). (D) Western
blot immunoreactivity for MT proteins in postmortem cere-
brospinal fluid from a patient with LSD, a patient with Par-
kinson disease (PD), and a CTR subject at 3 loading volumes
(25, 15, and 5ll).
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Fig S4C). Thus, blood MTs likely mark a process that is
pathobiologically linked to MLD and other LSDs.
MTs Are Dynamic Markers of Disease
Progression and Therapeutic Response
GLD, also known as Krabbe disease, is an LSD that
causes rapidly progressive neurologic deterioration and
death in early childhood. Transplantation of hematopoietic
stem cells from healthy donors in newborns with infantile
Krabbe disease can favorably alter the natural history of
the disease upon trafficking of transplant-derived cells to
the brain, where they become an in situ source of replace-
ment enzyme.
19,20 GLD mice model this rapidly progres-
sive CNS involvement as well as the response to
treatment.
21,22 We thus used this model to investigate MT
expression at progressive disease stages and in response to
hematopoietic stem cell transplantation.
MT expression in GLD mice dramatically increased
from the presymptomatic stage (at 9–12 days postnatal)
to the late symptomatic stage (at 35 days postnatal) in
both blood cells and brain homogenates (Fig 4A). GLD
animals underwent hematopoietic stem cell transplanta-
tion from WT donors at postnatal day 8. At 40 days of
age, transplanted mice showed only mild symptoms con-
sistent with a response to treatment, as previously
reported.
21,22 Remarkably, MT expression levels in
treated animals were significantly lower than the levels
measured in untreated age-matched GLD mice, which
were moribund at this disease stage (see Fig 4A). These
data indicate that MT expression may serve as a marker
of disease progression and response to treatment.
MT overexpression could exert its effects through
Lrp2/megalin, a member of the low-density lipoprotein
receptor gene family with both endocytic and signal
transduction functions.
23–25 Lrp2 mRNA levels in brain
extracts significantly increased along the course of the
disease in GLD mice, but not EAE mice (used as con-
trols of specificity; see Fig 4B).
We further explored the relationship between MT
expression and disease progression in patients with the
FIGURE 4.
FIGURE 4: Metallothioneins (MTs) are a dynamic marker of
disease progression and response to treatment. (A) Relative
abundance of MT1 and MT2 mRNA in blood cells of pre-
symptomatic (9–12 days, n59) and late symptomatic (25–
35 days, n518) globoid cell leukodystrophy (GLD) mice and
in the brain tissue of presymptomatic (9–12 days, n58),
late symptomatic (35 days, n56), and transplanted (40
days, n53) GLD mice compared to age-matched controls
(mean6standard error of the mean [SEM]; **p<0.01).
PBMC5peripheral blood mononuclear cell. (B) Relative
abundance of Lrp2 mRNA in brain of presymptomatic and
late symptomatic GLD and experimental autoimmune
encephalomyelitis (EAE) mice, compared to age-matched
wild-type animals and complete Freund adjuvant–treated
animals, respectively (mean6SEM; n55–9; **p<0.01). (C)
Comparison of the correlation between relative mRNA
abundance of the average of MT1A, MT1E, MT2A, and MTE
and age (expressed in months) for early onset metachro-
matic leukodystrophy (MLD) patients (dark gray squares)
and for age-matched healthy controls (CTR; light gray dots).
Pearson correlation coefficient50.617 (p50.0432) for
patients and 0.474 (p50.119) for controls.
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invariably presents itself between 12 and 24 months of
age and progresses more homogeneously with time than
in other subtypes.
5 We used patient age at the time of
blood drawing as an approximate indicator of disease
progression and correlated MT expression to age at blood
drawing. MT expression in blood increased in correlation
with the patients’ age at drawing (see Fig 4C; Pearson
correlation coefficient50.617; p50.0432). In contrast,
MTs did not correlate with age in healthy controls (Pear-
son correlation coefficient50.474; p50.119).
MTs Play a Role in Oxidative Stress and
Neuroinflammation In Vitro
Microglia activation and neuroinflammation play a piv-
otal role in the pathogenesis of LSDs affecting the CNS.
Microglia activation is a constant finding in LSD brains
and triggers focal inflammation that precedes demyelin-
ation and/or neurodegeneration.
22,26 MTs, however,
appear to be chiefly expressed in astrocytes of diseased
brain, as suggested by our data (see Fig 2B) and those of
others.
27
We started to investigate how crosstalk between
microglia and astrocytes relates to MT expression. MT
transcripts increased in pure mouse astrocyte cultures
upon contact with a microglia-conditioned medium. MT
expression in astrocytes increased even more significantly
in culture with a medium conditioned by LPS-activated
microglia (Fig 5A). These initial results implied a rela-
tionship between microglia resting/activated status and
MT expression by surrounding astrocytes. This prompted
us to further explore the microglia–astrocyte crosstalk in
a coculture constituted of approximately 5% microglial
cells and 95% astrocytes.
When GLD cells were put in in vitro culture, MT
expression returned to normal levels over time, suggesting
that the MT overexpression observed in vivo may be a
response to the extracellular milieu more than to intracel-
lular stimuli (see Fig 5B; see also Supplementary Fig 5
for the effects of serum on MT expression). We thus lim-
ited our analysis to WT cells.
To dissect the relation of MTs to inflammation and
oxidative stress, we stimulated astrocyte–microglia cocul-
tures with proinflammatory (LPS) and pro-oxidative
(H2O2 with glutathione depletion) stimuli, alone or pre-
treated with dexamethasone, an anti-inflammatory, or
Trolox, an antioxidative drug. As expected, MT expres-
sion increased in response to proinflammatory and pro-
oxidative stimuli (see Fig 5C). Surprisingly, pretreatment
with dexamethasone did not block LPS- or oxidative
stress–induced MT expression. Instead, pretreatment with
dexamethasone generally increased MT expression. Pre-
treatment with an antioxidant blocked MT expression in
response to oxidative stress, but had no effect on MT
expression per se nor in response to LPS (see Fig 5C).
Interestingly, the addition of 10% serum from late-
symptomatic GLD mice to WT astrocyte–microglia
cocultures was sufficient to significantly increase MT
expression compared to WT serum, independently from
astrocyte activation (as monitored by the expression of
chemokine Cxcl11; see Fig 5C). Serum of affected mice
thus may contain unidentified soluble factors that induce
a cellular response leading to an increase in MT
expression.
Discussion
LSDs cause immeasurable burden for affected children
and their families, as well as public health. As a group,
these are common childhood genetic disorders, with an
estimated combined frequency of 1 in 7,700 live births.
28
In these diseases, autosomal or X-linked recessive muta-
tions reduce or eliminate the activity of a variety of lyso-
somal enzymes.
28 Delivery of replacement enzymes is
particularly challenging in LSDs that affect the central
nervous system. Some early phase clinical trials are begin-
ning to test the efficacy of enzyme delivery by means of
either direct brain gene transfer or lentivirus-modified
patient-derived hematopoietic stem cells.
8 Simple circu-
lating biomarkers that inform about CNS pathology in
LSDs would be beneficial for accelerating these efforts.
Here we began to delineate a potential biomarker
for MLD and possibly other LSDs: overexpression of the
MT gene family in T cells derived from patient blood.
MTs were identified based on an mRNA-wide search
and replicated in independent patient samples. MT
expression was elevated in both blood cells and brain of
patients. The relative abundance of the transcripts in
brain from MLD patients was substantially higher than
that observed in T lymphocytes, suggesting that increased
expression of MTs could be directly linked to disease
pathogenesis in the most affected tissue.
This marker could be more generally useful in
LSDs beyond its association with MLD. In human and
mouse brains representing other LSDs characterized by
nervous tissue involvement, MTs were generally overex-
pressed. Important for developing a molecular marker of
treatment response, our study suggests that MT expres-
sion correlates with disease progression and disease modi-
fication, as shown in MLD patients and in a mouse
model of globoid cell leukodystrophy. Excitingly, when
the model mice were transplanted with normal hemato-
poietic stem cells (in which transplant-derived cells traffic
to the brain and become an in situ source of replacement
Cesani et al: Metallothioneins and LSDs
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MT expression.
Disease specificity is valuable, but not essential, for
markers of a progressive molecular disease process and
therapeutic response. Satisfyingly, MT overexpression in
peripheral blood cells appears to be preferentially associ-
ated with LSDs and was not observed in blood of
patients with multiple sclerosis, Parkinson disease, or
Huntington disease, nor in blood and brain of mice
modeling multiple sclerosis throughout the progression
of the disease. Although MT overexpression marks a
molecular process that may be relevant to neurodegenera-
tive disorders as well,
29–31 to our knowledge, this is the
first report of increased MT levels in peripheral cells of
patients with a neurologic disease.
Mechanistically, we hypothesize that MT expression
in LSDs is a response to oxidative and inflammatory
processes that are associated with the block of autophagy,
which has been shown to be a direct consequence of
lysosomal dysfunction.
32,33 Our in vitro experiments on
purified astrocyte–microglia cocultures suggest a complex
crosstalk between microglia activation and MT expression
in astrocytes and indicate that an as yet unidentified
soluble factor present in the serum of GLD mice is
FIGURE 5: Metallothioneins (MTs) play a role in oxidative stress and neuroinflammation in vitro. (A) Relative MT1 (left-hand panel)
and MT2 (right-hand panel) mRNA expression in pure mouse astrocyte cultures after 6 (dark gray bars) and 24 (light gray bars) hours
of contact with conditioned medium from resting or lipopolysaccharide (LPS)-activated microglia, respectively, compared to LPS-
treated control astrocytes (*p<0.05, **p<0.01). (B) Relative MT1 and MT2 mRNA expression in cells freshly dissected from the brain
(0 days in culture) and astrocyte–microglia cocultures (3, 7, 10, and 14 days in culture) isolated from 30-day old globoid cell leukodys-
trophy (GLD) mice, as compared to matched wild-type (WT) samples (n54–8; mean6standard error of the mean [SEM]). (C) Relative
MT1 and MT2 mRNA expression in WT astrocyte–microglia cocultures exposed to proinflammatory (LPS) and pro-oxidative
(H2O21L-buthionine-sulfoximine (BSO)) stimuli, alone or combined with 1 of the following 4 elements: dexamethasone, an anti-
inflammatory; Trolox, an antioxidative drug; 10% serum from WT mice; or 10% serum from late symptomatic GLD mice (n56–16;
mean6SEM; **p<0.01, n.s5p>0.05 compared to control condition [first column];
§p<0.05,
§§p<0.01, n.s.5p>0.05 compared to
dexamethasone-, Trolox-, or WT serum–treated controls). Astrocyte activation was assessed by CXCL11 expression (25absence of
transcript;15moderate presence of transcript; 115strong presence of transcript).
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134 Volume 75, No. 1sufficient to stimulate MT expression in cultured glial
cells. Upregulation of MTs may play a role in mitigating
the abovementioned LSD-associated inflammation and
oxidative stress.
34,35 Moreover, the specific increase in
Lrp2 receptor in the LSD setting suggests, for the first
time to our knowledge, a positive correlation between
MT and Lrp2 levels in the central nervous system. These
observations may help in further elucidating the role of
MTs in the pathobiology of LSDs.
This study has the merit of evaluating MT levels
on multiple gene and protein expression platforms and
in multiple human tissues, including T cells, brain, and
CSF, as well as in multiple mouse models. However, lim-
itations should also be kept in mind when interpreting
these observations. Biomarker development is a difficult
process that proceeds through multiple clinical phases.
36
Many markers fail at various stages of this process. Repli-
cation of the candidate markers identified here in much
larger, independent, and longitudinal patient populations
will be needed to develop these leads into a mature clini-
cal marker. Moreover, transitioning the biomarker to a
simple clinically feasible platform that uses routinely
TABLE. Genes Most Differentially Expressed in Metachromatic Leukodystrophy Patients Compared to
Age- and Sex-Matched Controls
Symbol Definition Fold Change p
MT1A Metallothionein 1A 1.544 0.000002
a
TIMD4 T-cell Ig and mucin domain containing 4 1.629 0.000022
MT2A Metallothionein 2A 1.530 0.000023
a
MT1E Metallothionein 1E 1.885 0.000028
a
C3orf14 1.672 0.000046
C20orf127 Metallothionein 1 pseudogene 3 1.531 0.000053
a
ATP1B1 ATPase, Na1/K1 transporting, beta 1 polypeptide 0.648 0.000070
b
KIAA1671 1.599 0.000078
RN7SK RNA, 7SK small nuclear 1.567 0.000106
MTE Metallothionein E 1.521 0.000156
a
RN7SK RNA, 7SK small nuclear 1.520 0.000423
CYP1B1 Cytochrome P450, fam 1, subfam B, polypeptide 1 3.212 0.000438
TNFSF13B TNF (ligand) superfamily, member 13b 1.573 0.000556
FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) 0.657 0.000897
b
TNFSF13B TNF (ligand) superfamily, member 13b 1.532 0.001947
EMP1 Epithelial membrane protein 1 1.582 0.002258
MCOLN2 Mucolipin 2 1.675 0.002264
EFHD1 EF-hand domain family, member D1 0.665 0.002987
b
PRDM1 PR domain containing 1, with ZNF domain 1.505 0.003636
MYB v-myb myeloblastosis viral oncogene homolog 1.616 0.004853
HOPX HOP homeobox 1.570 0.005710
GZMH Granzyme H (cathepsin G-like 2, protein h-CCPX) 1.946 0.008254
HS.390407 BX097705 NCI_CGAP_Kid5 1.570 0.009935
C12orf48 2.922 0.010243
GNLY Granulysin 2.395 0.012963
GNLY Granulysin 2.285 0.013042
Genes are ranked by probability value.
aGenes belonging to the metallothionein family.
bUnderexpressed genes.
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goal of further investigation.
In conclusion, direct analysis of LSD brain tissues
and gene expression analysis performed on the blood of
MLD patients revealed MTs as a novel, potential bio-
marker of disease progression for this class of diseases.
The analysis performed on various LSDs suggests that
MT expression changes could reflect a core molecular
pathway and potentially an early marker of treatment
response. Moreover, these findings provide a novel clue
into the molecular mechanisms of tissue damage in LSD
brains.
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